Crinetics Pharmaceuticals, Inc. — Form 8-K
Filed July 6, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 68/100
What the filing says
Vertex Pharmaceuticals (parent, ~$2.7B market cap) agreed to acquire Crinetics Pharmaceuticals in an all-cash merger at $85 per share effective July 6, 2026. Crinetics shareholders will receive $85.00 per share with no other consideration. The transaction includes equity award treatment (stock options accelerated and cashed out; RSUs cashed out; ESPP terminated), employee retention, and customary termination fees. Merger sub will merge with Crinetics, which continues as surviving corporation. Financing committed via debt commitment letter.
Why this rating
For Crinetics (~$2.7B market cap), this $9.0B+ transaction (105.8M shares × $85 = ~$9.0B equity value) represents 333% of company size—materially alters trajectory via acquisition. Relative to Vertex's size (much larger), impact is smaller. Deal appears fairly priced, no major contingencies except regulatory approval; significant but not transformational for either party alone.
See more from July 6, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.